Table 6 Comparison of outcomes according to the follow-up periods.

From: Long-term (2–5 years) adverse clinical outcomes associated with ZES versus SES, PES and EES: A Meta-Analysis

Follow-up (years)

Total number of patients treated with ZES (n)

Total number of patients treated with SES, PES or EES (n)

Type of DES versus ZES

Analytic report (RR with 95% CI)

2 years

1222

1213

SES versus ZES

No significant difference was observed in ST

2 years

1383

1384

PES versus ZES

2 years

2100

2098

EES versus ZES

3 years

150

154

SES versus ZES

4 years

1140

1152

EES versus ZES

4 years

1174

1236

SES versus ZES

Definite or probable ST significantly favored ZES [1.98 (1.22–3.23); p = 0.006

5 years

1469

1278

SES versus ZES

5 years

921

915

PES versus ZES

  1. Abbreviations: ZES: zotarolimus eluting stents, SES: sirolimus eluting stents, PES: paclitaxel eluting stents, EES: everolimus eluting stents, DES: drug eluting stents, RR: risk ratios, CI: confidence intervals, ST: stent thrombosis.